Literature DB >> 12393768

Efficacy of intravenous magnesium in neuropathic pain.

S Brill1, P M Sedgwick, W Hamann, P P Di Vadi.   

Abstract

BACKGROUND: Postherpetic neuralgia is a complication of acute herpes zoster characterized by severe pain and paraesthesia in the skin area affected by the initial infection. There is evidence that the N-methyl-D-aspartate receptor is involved in the development of hypersensitivity states and it is known that magnesium blocks the N-methyl-D-aspartate receptor.
METHOD: A double-blind, placebo-controlled, cross-over study was conducted in which magnesium sulphate was administered as an i.v. infusion. Spontaneous pain was recorded and qualitative sensory testing with cotton wool was performed in seven patients with postherpetic neuralgia before and after the i.v. administration of either magnesium sulphate 30 mg kg(-1) or saline.
RESULTS: During the administration, pain scores were significantly lower for magnesium compared with placebo at 20 and 30 min (P=0.016) but not at 10 min. I.V. magnesium sulphate was safe, well-tolerated and effective in patients with postherpetic neuralgia.
CONCLUSION: The present study supports the concept that the N-methyl-D-aspartate receptor is involved in the control of postherpetic neuralgia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393768

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  17 in total

Review 1.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks.

Authors:  Angela Mailis; Paul Taenzer
Journal:  Pain Res Manag       Date:  2012 May-Jun       Impact factor: 3.037

2.  Intravenous lidocaine and magnesium for management of intractable trigeminal neuralgia: a case series of nine patients.

Authors:  Young-Chang P Arai; Noboru Hatakeyama; Makoto Nishihara; Masahiko Ikeuchi; Makoto Kurisuno; Tatsunori Ikemoto
Journal:  J Anesth       Date:  2013-05-28       Impact factor: 2.078

3.  Gabapentin and (S)-pregabalin decrease intracellular D-serine concentrations in PC-12 cells.

Authors:  Nagendra S Singh; Rajib K Paul; Marc C Torjman; Irving W Wainer
Journal:  Neurosci Lett       Date:  2012-12-27       Impact factor: 3.046

4.  Magnesium sulfate attenuates tourniquet pain in healthy volunteers.

Authors:  Tsuyoshi Satsumae; Hiroshi Yamaguchi; Shinichi Inomata; Makoto Tanaka
Journal:  J Anesth       Date:  2012-10-07       Impact factor: 2.078

Review 5.  The placebo response: relationship to outcomes in trials of postherpetic neuralgia.

Authors:  Gordon Irving
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

6.  Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain.

Authors:  L J Rondón; A M Privat; L Daulhac; N Davin; A Mazur; J Fialip; A Eschalier; C Courteix
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

Review 7.  Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials.

Authors:  Andrea L Nicol; Robert W Hurley; Honorio T Benzon
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 8.  Expanding Role of NMDA Receptor Antagonists in the Management of Pain.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

9.  Perioperative systemic magnesium sulphate to minimize acute and chronic post-thoracotomy pain: a prospective observational study.

Authors:  Verena Ghezel-Ahmadi; David Ghezel-Ahmadi; Joachim Schirren; Charalambos Tsapopiorgas; Grietje Beck; Servet Bölükbas
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

Review 10.  Magnesium for Pain Treatment in 2021? State of the Art.

Authors:  Véronique Morel; Marie-Eva Pickering; Jonathan Goubayon; Marguérite Djobo; Nicolas Macian; Gisèle Pickering
Journal:  Nutrients       Date:  2021-04-21       Impact factor: 6.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.